S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$134.30
+0.3%
$129.20
$74.75
$142.00
$51.78B1.22.98 million shs2.12 million shs
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$7.11
-0.7%
$6.88
$6.33
$8.38
$15.88B1.1242,151 shs76,862 shs
Insulet Co. stock logo
PODD
Insulet
$164.73
-0.9%
$175.14
$125.82
$335.91
$11.53B0.98874,858 shs589,071 shs
ResMed Inc. stock logo
RMD
ResMed
$177.61
+2.2%
$186.42
$132.24
$243.52
$26.12B0.671.01 million shs1.58 million shs
Teleflex Incorporated stock logo
TFX
Teleflex
$207.38
-0.4%
$227.28
$177.63
$276.43
$9.77B1.11256,980 shs154,262 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-1.95%-4.60%-0.64%+5.03%+12.55%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
+0.24%+4.54%+4.45%+0.72%+1.35%
Insulet Co. stock logo
PODD
Insulet
-3.73%-6.28%-3.16%-18.46%-48.25%
ResMed Inc. stock logo
RMD
ResMed
-5.95%-10.30%-9.00%+0.64%-22.00%
Teleflex Incorporated stock logo
TFX
Teleflex
-0.92%-4.58%-3.80%-15.48%-19.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DexCom, Inc. stock logo
DXCM
DexCom
4.2647 of 5 stars
1.54.00.04.72.72.53.1
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/AN/AN/AN/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
4.6724 of 5 stars
3.43.00.04.92.40.83.1
ResMed Inc. stock logo
RMD
ResMed
4.8232 of 5 stars
3.41.04.24.52.81.72.5
Teleflex Incorporated stock logo
TFX
Teleflex
4.7465 of 5 stars
3.33.01.73.92.42.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.405.29% Upside
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
2.50
Moderate BuyN/AN/A
Insulet Co. stock logo
PODD
Insulet
2.80
Moderate Buy$243.2147.64% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$199.2012.16% Upside
Teleflex Incorporated stock logo
TFX
Teleflex
2.60
Moderate Buy$267.5028.99% Upside

Current Analyst Ratings

Latest DXCM, FSNUY, RMD, TFX, and PODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
4/3/2024
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$148.00 ➝ $161.00
4/1/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$215.00 ➝ $224.00
3/27/2024
ResMed Inc. stock logo
RMD
ResMed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$215.00
3/12/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$165.00
2/26/2024
Insulet Co. stock logo
PODD
Insulet
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$214.00 ➝ $213.00
2/23/2024
Insulet Co. stock logo
PODD
Insulet
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$250.00 ➝ $230.00
2/23/2024
Insulet Co. stock logo
PODD
Insulet
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$190.00 ➝ $225.00
2/23/2024
Teleflex Incorporated stock logo
TFX
Teleflex
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$285.00
2/23/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$272.00 ➝ $265.00
2/23/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$270.00 ➝ $265.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B14.29$2.04 per share65.98$5.35 per share25.10
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$24.01B0.66$2.19 per share3.24$15.07 per share0.47
Insulet Co. stock logo
PODD
Insulet
$1.70B6.80$3.62 per share45.51$10.49 per share15.70
ResMed Inc. stock logo
RMD
ResMed
$4.22B6.19$7.50 per share23.67$28.11 per share6.32
Teleflex Incorporated stock logo
TFX
Teleflex
$2.97B3.28$18.58 per share11.16$94.49 per share2.19

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.31102.5260.222.3514.95%28.31%9.74%4/25/2024 (Confirmed)
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
-$639.61M$0.1164.646.97N/A0.71%4.88%2.02%N/A
Insulet Co. stock logo
PODD
Insulet
$206.30M$2.9156.6142.573.1112.16%32.19%7.93%5/9/2024 (Confirmed)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.0529.3621.552.2919.77%23.86%14.78%4/25/2024 (Confirmed)
Teleflex Incorporated stock logo
TFX
Teleflex
$356.33M$7.5327.5413.642.0111.98%14.98%8.87%5/2/2024 (Estimated)

Latest DXCM, FSNUY, RMD, TFX, and PODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Insulet Co. stock logo
PODD
Insulet
$0.39N/A-$0.39N/AN/AN/A  
4/25/2024N/A
DexCom, Inc. stock logo
DXCM
DexCom
$0.27N/A-$0.27N/AN/AN/A  
4/25/2024N/A
ResMed Inc. stock logo
RMD
ResMed
$1.93N/A-$1.93N/AN/AN/A  
2/22/2024Q4 2023
Insulet Co. stock logo
PODD
Insulet
$0.67$1.40+$0.73$1.36$461.26 million$509.80 million    
2/22/2024Q4 23
Teleflex Incorporated stock logo
TFX
Teleflex
$3.26$3.38+$0.12$6.10$769.01 million$773.90 million      
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
1/24/2024Q2 24
ResMed Inc. stock logo
RMD
ResMed
$1.81$1.88+$0.07$2.34$1.15 billion$1.16 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$0.172.39%N/A154.56%N/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.921.08%+5.66%31.74%12 Years
Teleflex Incorporated stock logo
TFX
Teleflex
$1.360.66%N/A18.06%N/A

Latest DXCM, FSNUY, RMD, TFX, and PODD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/22/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.57%2/29/20243/1/20243/15/2024
1/24/2024
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.481.12%2/7/20242/8/20243/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
0.36
1.54
1.44
Insulet Co. stock logo
PODD
Insulet
1.86
3.51
2.62
ResMed Inc. stock logo
RMD
ResMed
0.27
3.11
1.89
Teleflex Incorporated stock logo
TFX
Teleflex
0.39
2.32
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
Insulet Co. stock logo
PODD
Insulet
0.90%
ResMed Inc. stock logo
RMD
ResMed
1.21%
Teleflex Incorporated stock logo
TFX
Teleflex
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600385.52 million383.93 millionOptionable
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
193,8652.23 billionN/ANot Optionable
Insulet Co. stock logo
PODD
Insulet
3,00070.02 million69.39 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140147.09 million145.31 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,50047.10 million46.43 millionOptionable

DXCM, FSNUY, RMD, TFX, and PODD Headlines

SourceHeadline
Which Is a Better Investment, Rxsight Inc or Teleflex Inc Stock?Which Is a Better Investment, Rxsight Inc or Teleflex Inc Stock?
aaii.com - April 18 at 1:09 PM
Teleflex Announces First Quarter 2024 Earnings Conference Call InformationTeleflex Announces First Quarter 2024 Earnings Conference Call Information
globenewswire.com - April 18 at 6:30 AM
Cerity Partners LLC Buys Shares of 13,175 Teleflex Incorporated (NYSE:TFX)Cerity Partners LLC Buys Shares of 13,175 Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 18 at 5:40 AM
Raymond James Financial Services Advisors Inc. Trims Holdings in Teleflex Incorporated (NYSE:TFX)Raymond James Financial Services Advisors Inc. Trims Holdings in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 15 at 4:27 AM
DekaBank Deutsche Girozentrale Has $1.74 Million Position in Teleflex Incorporated (NYSE:TFX)DekaBank Deutsche Girozentrale Has $1.74 Million Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 14 at 5:19 AM
Guru Fundamental Report for TFX - Benjamin GrahamGuru Fundamental Report for TFX - Benjamin Graham
nasdaq.com - April 13 at 9:49 AM
Sequoia Financial Advisors LLC Makes New $1.72 Million Investment in Teleflex Incorporated (NYSE:TFX)Sequoia Financial Advisors LLC Makes New $1.72 Million Investment in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 13 at 6:40 AM
Teleflex Incorporated (NYSE:TFX) Shares Sold by Lawson Kroeker Investment Management Inc. NETeleflex Incorporated (NYSE:TFX) Shares Sold by Lawson Kroeker Investment Management Inc. NE
marketbeat.com - April 11 at 3:56 PM
Villere ST Denis J & Co. LLC Reduces Stock Position in Teleflex Incorporated (NYSE:TFX)Villere ST Denis J & Co. LLC Reduces Stock Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 8 at 12:23 PM
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATCTeleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
zacks.com - April 8 at 9:21 AM
Teleflex Unveils Advanced Tissue Control for UroLift 2 System, Revolutionizing BPH TreatmentTeleflex Unveils Advanced Tissue Control for UroLift 2 System, Revolutionizing BPH Treatment
msn.com - April 5 at 10:39 AM
Boston Trust Walden Corp Has $56.82 Million Holdings in Teleflex Incorporated (NYSE:TFX)Boston Trust Walden Corp Has $56.82 Million Holdings in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 4 at 11:30 PM
Teleflex catheterization kit recall linked to 10 injuries, 1 deathTeleflex catheterization kit recall linked to 10 injuries, 1 death
medtechdive.com - April 4 at 2:34 PM
Research Analysts Issue Forecasts for Teleflex Incorporateds FY2025 Earnings (NYSE:TFX)Research Analysts Issue Forecasts for Teleflex Incorporated's FY2025 Earnings (NYSE:TFX)
marketbeat.com - April 3 at 6:31 AM
Teleflex launches UroLift 2 with advanced tissue controlTeleflex launches UroLift 2 with advanced tissue control
massdevice.com - April 2 at 5:35 PM
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate TypesTeleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
finance.yahoo.com - April 2 at 8:41 AM
Teleflex Sets Ambitious Climate Targets, Validated by Science Based Targets InitiativeTeleflex Sets Ambitious Climate Targets, Validated by Science Based Targets Initiative
msn.com - April 1 at 12:54 AM
AMI Asset Management Corp Has $18.86 Million Stock Position in Teleflex Incorporated (NYSE:TFX)AMI Asset Management Corp Has $18.86 Million Stock Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - March 30 at 11:21 PM
LGT Capital Partners LTD. Purchases 190,950 Shares of Teleflex Incorporated (NYSE:TFX)LGT Capital Partners LTD. Purchases 190,950 Shares of Teleflex Incorporated (NYSE:TFX)
marketbeat.com - March 29 at 9:43 AM
Teleflex Incorporated (NYSE:TFX) Short Interest Down 42.0% in MarchTeleflex Incorporated (NYSE:TFX) Short Interest Down 42.0% in March
marketbeat.com - March 28 at 10:30 AM
Teleflex’s Climate Targets Validated by the Science Based Targets InitiativeTeleflex’s Climate Targets Validated by the Science Based Targets Initiative
finance.yahoo.com - March 28 at 8:09 AM
Teleflexs Climate Targets Validated by the Science Based Targets InitiativeTeleflex's Climate Targets Validated by the Science Based Targets Initiative
globenewswire.com - March 28 at 6:30 AM
Teleflex Incorporateds (NYSE:TFX) Intrinsic Value Is Potentially 60% Above Its Share PriceTeleflex Incorporated's (NYSE:TFX) Intrinsic Value Is Potentially 60% Above Its Share Price
finance.yahoo.com - March 24 at 5:05 PM
Teleflex Incorporated (NYSE:TFX) Shares Sold by Vanguard Group Inc.Teleflex Incorporated (NYSE:TFX) Shares Sold by Vanguard Group Inc.
marketbeat.com - March 20 at 4:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA

OTCMKTS:FSNUY
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Teleflex logo

Teleflex

NYSE:TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.